Culley C. Carson III, MD
Rhodes Distinguished Professor and Chief of Urology
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Kevin T. McVary, MD
Professor of Urology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois

Martin M. Miner, MD
Director, Men's Health Center
Miriam Hospital
Clinical Associate Professor of Family Medicine and Urology
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Endocrinologists, urologists, primary care physicians, cardiologists, specialists, and other healthcare professionals interested in the management and treatment of hypogonadism.

Hypogonadism is an underdiagnosed and therefore undertreated condition of men that can be associated with serious comorbid conditions. In light of these facts, screening, recognition, and treatment by any provider seeing men who are at risk for hypogonadism should be encouraged.

At the conclusion of this activity, participants should be better able to:

  1. Evaluate evidence related to the relationship between testosterone therapy and the development of benign prostatic hyperplasia (BPH)
  2. Review the role that testosterone therapy may have in the management of lower urinary tract symptoms in hypogonadal men with BPH
  3. Optimally manage hypogonadism to improve treatment outcomes

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the evaluation and posttest to CogniMed Inc. A link to the evaluation and posttest is provided upon completion of the activity. Please allow 4 to 6 weeks for the delivery of your statement.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will be discussion about the use of products for non–FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Michelle Montgomery, Director of Continuing Education, has nothing to disclose.
Mark Nadeau, MD, Content Reviewer, has nothing to disclose.

CogniMed Inc. Staff
Roseann MacLachlan, Senior Program Manager, has nothing to disclose.
Estelle Perera, Director, Scientific Affairs, and Medical Writer, has nothing to disclose.
Chantel Phipany, Vice President and Director, has nothing to disclose.
Elizabeth Stanton, Editor, has nothing to disclose.

Culley C. Carson III, MD, receives research support from, is a consultant for, and serves on the speakers bureaus of American Medical Systems; Auxilium Pharmaceuticals, Inc.; Eli Lilly and Company; and GlaxoSmithKline.

Kevin T. McVary, MD, receives research support from, is a consultant for, and/or serves on the speakers bureaus of Allergan, Inc.; Eli Lilly and Company; GlaxoSmithKline; the National Cancer Institute; the National Institutes of Health; and Watson Pharmaceuticals, Inc.

Martin M. Miner, MD, receives research support from Auxilium Pharmaceuticals, Inc. He is a consultant for Abbott Laboratories; Auxilium Pharmaceuticals, Inc.; Endo Pharmaceuticals; and Lilly USA, LLC.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Sponsored by CogniMed Inc.

This activity is supported by an independent educational grant provided by Abbott Laboratories.

This activity consists of audio clips synced with slides. Successful completion is achieved by listening to the audio and reading the slides, reflecting on the content's implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 0.5 hour.

This activity was originally released August 31, 2012, and is eligible for credit through August 31, 2013.

© 2012 CogniMed Inc. All rights reserved.            TU14141             August 2012